PCM
LXRX icon

Piermont Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Piermont Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-14,400
Closed -$177K – 252
2017
Q3 		$177K Sell
14,400
-15,310
-52% -$226K 0.06% 241
2017
Q2 		$489K Sell
29,710
-5,160
-15% -$79.9K 0.14% 230
2017
Q1 		$500K Hold
34,870
– – 0.12% 230
2016
Q4 		$482K Sell
34,870
-670
-2% -$10.8K 0.11% 229
2016
Q3 		$642K Buy
+35,540
New +$572K 0.15% 207

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Piermont Capital Management's LXRX Position: Q4 2017 in Review

Piermont Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2017, closing a stake of 14,400 shares — an estimated $177K sold.

Piermont Capital Management first reported a position in LXRX in Q3 2016 and held it in 5 quarters. The position peaked at $642K in Q3 2016. 133 funds tracked by Wall St. Rank hold LXRX as of Q4 2017.

  • Piermont Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Piermont Capital Management sold 14,400 Lexicon Pharmaceuticals shares in Q4 2017, an estimated $177K.
  • Piermont Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • Piermont Capital Management's Lexicon Pharmaceuticals position peaked at $642K in Q3 2016.
  • 133 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2017.

Based on Piermont Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.